Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:15:57.460Z.
Consensus retrieved: 2026-10-06T09:36:21.360Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:15:57.460Z.
Quote observation: 2026-10-06T13:43:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d9f471510e2ba483dadfaa738129fdacbeb72ec081face8194c47abf0e776528
Forward PE Ratio (N/A) = Dated Quote Price ($3.55) / Consensus Forward EPS ($-17.89)
FORWARD PE RATIO
N/A
Bolt Biotherapeutics, Inc.
Market Cap
$6.82M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | $6.82M | N/A |
| Aclarion, Inc. (ACON)vs › | $6.86M | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.91M | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.63M | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.17M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.21M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.37M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.40M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.55, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-17.89 | $-17.89 – $-17.89 | 2 | n/m |
| 2027-12-31 | $-20.19 | $-24.74 – $-15.64 | 2 | n/m |
| 2028-12-31 | $-30.84 | $-30.84 – $-30.84 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
